# Babcock & Wilcox Enterprises, Inc.: financial statements, quarterly

BW · NYSE · CIK 1630805 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bw.md) · [Financials](/companies/bw/financials.md) · [Filings](/companies/bw/filings.md) · [Insiders](/companies/bw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [239](/filings/0001630805-24-000069.md) | [(185) d](/filings/0001630805-26-000018.md) | [164](/filings/0001630805-25-000019.md) | [151](/filings/0001630805-25-000062.md) | [153](/filings/0001630805-25-000090.md) | [136 d](/filings/0001630805-26-000018.md) | [149](/filings/0001630805-26-000030.md) | [139](/filings/0001630805-26-000068.md) | [149](/filings/0001630805-25-000090.md) | [139 d](/filings/0001630805-26-000018.md) | [214](/filings/0001630805-26-000030.md) | [320](/filings/0001630805-26-000068.md) |
| Cost of revenue | $m | [186](/filings/0001630805-24-000069.md) | [(138) d](/filings/0001630805-26-000018.md) | [126](/filings/0001630805-25-000019.md) | [118](/filings/0001630805-25-000062.md) | [117](/filings/0001630805-25-000090.md) | [109 d](/filings/0001630805-26-000018.md) | [121](/filings/0001630805-26-000030.md) | [97.4](/filings/0001630805-26-000068.md) | [112](/filings/0001630805-25-000090.md) | [106 d](/filings/0001630805-26-000018.md) | [171](/filings/0001630805-26-000030.md) | [273](/filings/0001630805-26-000068.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [45.7](/filings/0001630805-24-000069.md) | [(8.5) d](/filings/0001630805-26-000018.md) | [32.2](/filings/0001630805-25-000019.md) | [36.6](/filings/0001630805-25-000062.md) | [33.3](/filings/0001630805-25-000090.md) | [26.1 d](/filings/0001630805-26-000018.md) | [28.3](/filings/0001630805-26-000030.md) | [33.3](/filings/0001630805-26-000068.md) | [29.8](/filings/0001630805-25-000090.md) | [26.7 d](/filings/0001630805-26-000018.md) | [44.4](/filings/0001630805-26-000030.md) | [33.7](/filings/0001630805-26-000068.md) |
| Operating income | $m | [5.5](/filings/0001630805-24-000069.md) | [(39.3) d](/filings/0001630805-26-000018.md) | [5.7](/filings/0001630805-25-000019.md) | [(4.4)](/filings/0001630805-25-000062.md) | [1.6](/filings/0001630805-25-000090.md) | [(4.4) d](/filings/0001630805-26-000018.md) | [(1.8)](/filings/0001630805-26-000030.md) | [7.0](/filings/0001630805-26-000068.md) | [6.5](/filings/0001630805-25-000090.md) | [5.9 d](/filings/0001630805-26-000018.md) | [(1.7)](/filings/0001630805-26-000030.md) | [11.8](/filings/0001630805-26-000068.md) |
| Interest expense | $m | [13.4](/filings/0001630805-23-000030.md) | [5.3 d](/filings/0001630805-25-000007.md) | [12.8](/filings/0001630805-24-000028.md) | [12.0](/filings/0001630805-25-000062.md) | [10.1](/filings/0001630805-25-000090.md) | [12.1 d](/filings/0001630805-25-000007.md) | [11.0](/filings/0001630805-26-000030.md) | [11.0](/filings/0001630805-26-000068.md) | [8.5](/filings/0001630805-25-000090.md) | [7.0 d](/filings/0001630805-26-000018.md) | [4.4](/filings/0001630805-26-000030.md) | [5.0](/filings/0001630805-26-000068.md) |
| Income tax | $m | [(0.3)](/filings/0001630805-24-000069.md) | [3.6 d](/filings/0001630805-26-000018.md) | [0.9](/filings/0001630805-25-000019.md) | [4.7](/filings/0001630805-25-000062.md) | [(0.5)](/filings/0001630805-25-000090.md) | [10.2 d](/filings/0001630805-26-000018.md) | [1.9](/filings/0001630805-26-000030.md) | [4.0](/filings/0001630805-26-000068.md) | [1.0](/filings/0001630805-25-000090.md) | [1.4 d](/filings/0001630805-26-000018.md) | [4.2](/filings/0001630805-26-000030.md) | [(1.1)](/filings/0001630805-26-000068.md) |
| Net income | $m | [(117)](/filings/0001630805-24-000069.md) | [(62.7) d](/filings/0001630805-26-000018.md) | [(16.8)](/filings/0001630805-25-000019.md) | [25.4](/filings/0001630805-25-000062.md) | [(5.3)](/filings/0001630805-25-000090.md) | [(63.2) d](/filings/0001630805-26-000018.md) | [(22.0)](/filings/0001630805-26-000030.md) | [(58.5)](/filings/0001630805-26-000068.md) | [35.1](/filings/0001630805-25-000090.md) | [9.2 d](/filings/0001630805-26-000018.md) | [(76.9)](/filings/0001630805-26-000030.md) | [14.3](/filings/0001630805-26-000068.md) |
| Diluted EPS | $ per share | [(1.35)](/filings/0001630805-24-000069.md) | not reported | [(0.23)](/filings/0001630805-25-000019.md) | [0.24](/filings/0001630805-25-000062.md) | [(0.10)](/filings/0001630805-25-000090.md) | not reported | [(0.26)](/filings/0001630805-26-000030.md) | [(0.63)](/filings/0001630805-26-000068.md) | [0.30](/filings/0001630805-25-000090.md) | not reported | [(0.60)](/filings/0001630805-26-000030.md) | [0.07](/filings/0001630805-26-000068.md) |
| Basic EPS | $ per share | [(1.35)](/filings/0001630805-24-000069.md) | not reported | [(0.23)](/filings/0001630805-25-000019.md) | [0.24](/filings/0001630805-25-000062.md) | [(0.10)](/filings/0001630805-25-000090.md) | not reported | [(0.26)](/filings/0001630805-26-000030.md) | [(0.63)](/filings/0001630805-26-000068.md) | [0.30](/filings/0001630805-25-000090.md) | not reported | [(0.60)](/filings/0001630805-26-000030.md) | [0.07](/filings/0001630805-26-000068.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [48.4](/filings/0001630805-24-000069.md) | [65.3](/filings/0001630805-26-000018.md) | [43.9](/filings/0001630805-25-000019.md) | [95.5](/filings/0001630805-25-000062.md) | [30.6](/filings/0001630805-25-000090.md) | [26.9](/filings/0001630805-26-000018.md) | [23.5](/filings/0001630805-26-000030.md) | [23.4](/filings/0001630805-26-000068.md) | [25.2](/filings/0001630805-25-000090.md) | [89.5](/filings/0001630805-26-000068.md) | [107](/filings/0001630805-26-000030.md) | [309](/filings/0001630805-26-000068.md) |
| Current assets | $m | [542](/filings/0001630805-23-000030.md) | [498](/filings/0001630805-25-000007.md) | [482](/filings/0001630805-24-000028.md) | [575](/filings/0001630805-24-000064.md) | [530](/filings/0001630805-24-000069.md) | [553](/filings/0001630805-26-000018.md) | [483](/filings/0001630805-25-000019.md) | [527](/filings/0001630805-25-000062.md) | [480](/filings/0001630805-25-000090.md) | [471](/filings/0001630805-26-000068.md) | [491](/filings/0001630805-26-000030.md) | [725](/filings/0001630805-26-000068.md) |
| Total assets | $m | [837](/filings/0001630805-23-000030.md) | [776](/filings/0001630805-25-000007.md) | [796](/filings/0001630805-24-000028.md) | [849](/filings/0001630805-24-000064.md) | [805](/filings/0001630805-24-000069.md) | [727](/filings/0001630805-26-000018.md) | [720](/filings/0001630805-25-000019.md) | [703](/filings/0001630805-25-000062.md) | [658](/filings/0001630805-25-000090.md) | [663](/filings/0001630805-26-000068.md) | [758](/filings/0001630805-26-000030.md) | [1,000](/filings/0001630805-26-000068.md) |
| Current liabilities | $m | [394](/filings/0001630805-23-000030.md) | [350](/filings/0001630805-25-000007.md) | [333](/filings/0001630805-24-000028.md) | [334](/filings/0001630805-24-000064.md) | [298](/filings/0001630805-24-000069.md) | [407](/filings/0001630805-26-000018.md) | [511](/filings/0001630805-25-000019.md) | [529](/filings/0001630805-25-000062.md) | [401](/filings/0001630805-25-000090.md) | [387](/filings/0001630805-26-000068.md) | [495](/filings/0001630805-26-000030.md) | [500](/filings/0001630805-26-000068.md) |
| Total liabilities | $m | [979](/filings/0001630805-23-000030.md) | [976](/filings/0001630805-25-000007.md) | [1,018](/filings/0001630805-24-000028.md) | [1,047](/filings/0001630805-24-000064.md) | [1,008](/filings/0001630805-24-000069.md) | [1,010](/filings/0001630805-26-000018.md) | [1,022](/filings/0001630805-25-000019.md) | [1,012](/filings/0001630805-25-000062.md) | [890](/filings/0001630805-25-000090.md) | [794](/filings/0001630805-26-000068.md) | [930](/filings/0001630805-26-000030.md) | [942](/filings/0001630805-26-000068.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(142)](/filings/0001630805-23-000030.md) | [(201)](/filings/0001630805-25-000007.md) | [(223)](/filings/0001630805-24-000028.md) | [(199)](/filings/0001630805-24-000064.md) | [(204)](/filings/0001630805-24-000069.md) | [(284)](/filings/0001630805-26-000018.md) | [(303)](/filings/0001630805-25-000019.md) | [(309)](/filings/0001630805-25-000062.md) | [(232)](/filings/0001630805-25-000090.md) | [(132)](/filings/0001630805-26-000068.md) | [(172)](/filings/0001630805-26-000030.md) | [57.4](/filings/0001630805-26-000068.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(28.2) d](/filings/0001630805-24-000069.md) | [8.2 d](/filings/0001630805-26-000018.md) | [(14.9)](/filings/0001630805-25-000019.md) | [(11.8) d](/filings/0001630805-25-000062.md) | [(69.5) d](/filings/0001630805-25-000090.md) | [(22.5) d](/filings/0001630805-26-000018.md) | [(8.5)](/filings/0001630805-26-000030.md) | [(25.3) d](/filings/0001630805-26-000068.md) | [(32.1) d](/filings/0001630805-25-000090.md) | [(3.0) d](/filings/0001630805-26-000018.md) | [17.8](/filings/0001630805-26-000030.md) | [(17.4) d](/filings/0001630805-26-000068.md) |
| Capital expenditure | $m | [5.0 d](/filings/0001630805-24-000069.md) | [(0.7) d](/filings/0001630805-26-000018.md) | [3.4](/filings/0001630805-25-000019.md) | [4.6 d](/filings/0001630805-25-000062.md) | [2.2 d](/filings/0001630805-25-000090.md) | [1.1 d](/filings/0001630805-26-000018.md) | [4.3](/filings/0001630805-26-000030.md) | [2.7 d](/filings/0001630805-26-000068.md) | [5.5 d](/filings/0001630805-25-000090.md) | [4.2 d](/filings/0001630805-26-000018.md) | [7.1](/filings/0001630805-26-000030.md) | [6.6 d](/filings/0001630805-26-000068.md) |
| Share repurchases | $m | [1.3 d](/filings/0001630805-24-000069.md) | [0.0 d](/filings/0001630805-26-000018.md) | [0.0](/filings/0001630805-24-000028.md) | [0.0 d](/filings/0001630805-25-000062.md) | [0.3 d](/filings/0001630805-25-000090.md) | [0.1 d](/filings/0001630805-26-000018.md) | not reported | not reported | [0.4 d](/filings/0001630805-25-000090.md) | [0.0 d](/filings/0001630805-26-000018.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [88.3](/filings/0001630805-23-000030.md) | [88.7](/filings/0001630805-24-000028.md) | [88.8](/filings/0001630805-24-000064.md) | [89.1](/filings/0001630805-24-000069.md) | [89.5](/filings/0001630805-25-000019.md) | [91.2](/filings/0001630805-25-000062.md) | [92.3](/filings/0001630805-25-000090.md) | [97.9](/filings/0001630805-26-000030.md) | [98.7](/filings/0001630805-26-000068.md) | [103](/filings/0001630805-25-000090.md) | [134](/filings/0001630805-26-000030.md) | [155](/filings/0001630805-26-000068.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 148,965,066 at 2026-08-04, from the cover of the [10-Q filed 2026-08-10](/filings/0001630805-26-000068.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.